Review of the nutritional benefits and risks related to intense sweeteners.

BACKGROUND: The intense sweeteners currently authorised in Europe comprise ten compounds of various chemical natures. Their overall use has sharply risen in the last 20 years. These compounds are mainly used to formulate reduced-calorie products while maintaining sweetness. METHODS: This extensive analysis of the literature reviews the data currently available on the potential nutritional benefits and risks related to the consumption of products containing intense sweeteners. RESULTS AND CONCLUSIONS: Regarding nutritional benefits, the available studies, while numerous, do not provide proof that the consumption of artificial sweeteners as sugar substitutes is beneficial in terms of weight management, blood glucose regulation in diabetic subjects or the incidence of type 2 diabetes. Regarding nutritional risks (incidence of type 2 diabetes, habituation to sweetness in adults, cancers, etc.), it is not possible based on the available data to establish a link between the occurrence of these risks and the consumption of artificial sweeteners. However, some studies underline the need to improve knowledge of the links between intense sweeteners consumption and certain risks

Review of the nutritional benefits and risks related to intense sweeteners

Unfortunately, the original version of this article [1] contained an error. The author’s names were included incorrectly, the surnames were presented before the forename: Bruyère Olivier, Ahmed H. Serge, Atlan Catherine, Belegaud Jacques, Bortolotti Murielle, Canivenc-Lavier Marie-Chantal, Charrière Sybil, Girardet Jean-Philippe, Houdart Sabine, Kalonji Esther, Nadaud Perrine, Rajas Fabienne, Slama Gérard and Margaritis Irène The author list has been corrected in the original article and is also included correctly below: Olivier Bruyère, Serge H. Ahmed, Catherine Atlan, Jacques Belegaud, Murielle Bortolotti, Marie-Chantal Canivenc-Lavier, Sybil Charrière, Jean-Philippe Girardet, Sabine Houdart, Esther Kalonji, Perrine Nadaud, Fabienne Rajas, Gérard Slama, Irène Margaritis (NB: erratum 1 p. doi: in volume 73, 49, published 23 October 2015, (eCollection 2015, PMID: 26500771, PMCID: PMC4619575))International audienceBackground : The intense sweeteners currently authorised in Europe comprise ten compounds of various chemical natures. Their overall use has sharply risen in the last 20 years. These compounds are mainly used to formulate reduced-calorie products while maintaining sweetness.Methods : This extensive analysis of the literature reviews the data currently available on the potential nutritional benefits and risks related to the consumption of products containing intense sweeteners.Results and Conclusions : Regarding nutritional benefits, the available studies, while numerous, do not provide proof that the consumption of artificial sweeteners as sugar substitutes is beneficial in terms of weight management, blood glucose regulation in diabetic subjects or the incidence of type 2 diabetes. Regarding nutritional risks (incidence of type 2 diabetes, habituation to sweetness in adults, cancers, etc.), it is not possible based on the available data to establish a link between the occurrence of these risks and the consumption of artificial sweeteners. However, some studies underline the need to improve knowledge of the links between intense sweeteners consumption and certain risks

Les médicaments hypocholestérolémiants chez l'enfant

Le traitement de l'hypercholestérolémie de l'enfant s'intègre dans le cadre de la prévention de la maladie coronaire prématurée de l'adulte. Le traitement médicamenteux doit donc être ciblé sur les hypercholestérolémies héréditaires, transmises sur le mode autosomique dominant (hypercholestérolémies familiales, déficience familiale en apolipoprotéine B100, dyslipidémie combinée familiale), dont on connaît l'importance du risque cardiovasculaire qui leur est associé chez l'adulte jeune. Au cours de ces affections, les médicaments hypocholestérolémiants sont indiqués chez les enfants dont la concentration plasmatique de LDL-cholestérol reste supérieure à 190 mg/dL après 6 mois de traitement diététique. La colestyramine dont plusieurs études contrôlées ont montré l'efficacité et la bonne tolérance chez l'enfant reste le traitement de première intention. Les statines peuvent être prescrites en relais de la colestyramine à partir de l'âge de 8 à 9 ans mais on manque encore à l'heure actuelle de données sur leur tolérance à long terme. Les fibrates peuvent également être utilisés en seconde intention, mais ils n'ont fait l'objet d'aucune étude contrôlée en pédiatrie

RETENTISSEMENT ARTERIEL DE L'HYPERCHOLESTEROLEMIE CHEZ L'ENFANT

PARIS-BIUM (751062103) / SudocCentre Technique Livre Ens. Sup. (774682301) / SudocSudocFranceF

Expression pédiatrique de l'hyperlipidémie familiale combinée (étude de 21 observations)

PARIS6-Bibl. St Antoine CHU (751122104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Maladies inflammatoires du tube digestif débutant avant l'âge de 2 ans

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Allergie au blé et maladie coeliaque, une association rare : à propos de 5 cas

REIMS-BU Santé (514542104) / SudocSudocFranceF

Le Nouveau Sans Frontieres.Méthode de Francais : t. III

240 tr.; 20 cm

Le Nouveau Sans Frontieres : t. III. Mé thode de Francais; Cahier d"Exercices

175 tr.; 20 cm